TWI222879B - Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder - Google Patents
Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder Download PDFInfo
- Publication number
- TWI222879B TWI222879B TW089102338A TW89102338A TWI222879B TW I222879 B TWI222879 B TW I222879B TW 089102338 A TW089102338 A TW 089102338A TW 89102338 A TW89102338 A TW 89102338A TW I222879 B TWI222879 B TW I222879B
- Authority
- TW
- Taiwan
- Prior art keywords
- todotin
- release
- composition according
- concentration
- controlled release
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000003932 urinary bladder Anatomy 0.000 title 1
- 238000013270 controlled release Methods 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 229910052704 radon Inorganic materials 0.000 claims description 17
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims description 17
- 239000007937 lozenge Substances 0.000 claims description 13
- 230000002079 cooperative effect Effects 0.000 claims description 6
- 206010020853 Hypertonic bladder Diseases 0.000 abstract description 17
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 6
- 229960004045 tolterodine Drugs 0.000 abstract description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 abstract description 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- 238000011049 filling Methods 0.000 description 16
- 239000002207 metabolite Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 206010013781 dry mouth Diseases 0.000 description 13
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 13
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 12
- 230000028327 secretion Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229960005434 oxybutynin Drugs 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 208000020629 overactive bladder Diseases 0.000 description 9
- 210000003296 saliva Anatomy 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 6
- 229940025084 amphetamine Drugs 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000002636 mycotoxin Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 2 — phenyl-5-tolyl Chemical group 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 231100000678 Mycotoxin Toxicity 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- UAGMSGKBTBVFJD-UHFFFAOYSA-L C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].[Na+].C(CO)(=O)[O-] Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].[Na+].C(CO)(=O)[O-] UAGMSGKBTBVFJD-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DSJYSRTZHXBOCX-UHFFFAOYSA-N ac1l9i4c Chemical compound O.O.O.O DSJYSRTZHXBOCX-UHFFFAOYSA-N 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9803871A SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Therapeutic method and formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI222879B true TWI222879B (en) | 2004-11-01 |
Family
ID=20413266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089102338A TWI222879B (en) | 1998-11-11 | 2000-02-11 | Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder |
| TW089102332A TWI267385B (en) | 1998-11-11 | 2000-02-11 | Controlled release bead, pharmaceutical formulation comprising the same and production thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089102332A TWI267385B (en) | 1998-11-11 | 2000-02-11 | Controlled release bead, pharmaceutical formulation comprising the same and production thereof |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6911217B1 (de) |
| EP (1) | EP1128819B1 (de) |
| JP (1) | JP3616011B2 (de) |
| KR (1) | KR100467384B1 (de) |
| CN (1) | CN1169522C (de) |
| AP (1) | AP1323A (de) |
| AR (1) | AR027815A1 (de) |
| AT (1) | ATE247458T1 (de) |
| AU (1) | AU762410B2 (de) |
| BG (1) | BG65149B1 (de) |
| BR (1) | BRPI9915142B8 (de) |
| CA (1) | CA2350061C (de) |
| CZ (1) | CZ299582B6 (de) |
| DE (1) | DE69910604T2 (de) |
| DK (1) | DK1128819T3 (de) |
| EA (1) | EA005074B1 (de) |
| EE (1) | EE05232B1 (de) |
| ES (1) | ES2204193T3 (de) |
| GE (1) | GEP20022833B (de) |
| HK (1) | HK1040917B (de) |
| HR (1) | HRP20010333B1 (de) |
| HU (1) | HU226582B1 (de) |
| ID (1) | ID30039A (de) |
| IL (1) | IL142809A0 (de) |
| IS (1) | IS2370B (de) |
| MA (1) | MA25325A1 (de) |
| MY (1) | MY122195A (de) |
| NO (1) | NO331399B1 (de) |
| NZ (1) | NZ511430A (de) |
| OA (1) | OA11673A (de) |
| PL (1) | PL195780B1 (de) |
| PT (1) | PT1128819E (de) |
| RS (1) | RS49891B (de) |
| SE (1) | SE9803871D0 (de) |
| SI (1) | SI1128819T1 (de) |
| SK (1) | SK284758B6 (de) |
| TW (2) | TWI222879B (de) |
| UA (1) | UA57165C2 (de) |
| WO (1) | WO2000027364A1 (de) |
| ZA (1) | ZA200103575B (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998003067A1 (en) * | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
| EP0957073A1 (de) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | 3,3-Diphenylpropylaminderivate |
| HUP0203028A3 (en) | 1999-11-11 | 2005-07-28 | Pharmacia Ab | Pharmaceutical formulation containing tolterodine and its use |
| US7101888B2 (en) * | 2002-08-28 | 2006-09-05 | Pharmacia & Upjohn Company | Oral liquid tolterodine composition |
| US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| MXPA05007767A (es) * | 2003-01-22 | 2006-01-31 | Pfizer Health Ab | Dosis reducida de tolterodina y otros agentes antimuscarinicos para tratar trastornos urinarios. |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| DE602004030931D1 (de) | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
| US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
| US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| EP1629834A1 (de) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung |
| JP2007527923A (ja) * | 2005-01-10 | 2007-10-04 | テバ ファーマシューティカル インダストリーズ リミティド | トルテロジンタルトレートの調製方法 |
| AU2006253007B2 (en) | 2005-05-31 | 2012-12-20 | Alimentary Health Ltd | Feline probiotic Bifidobacteria |
| EP2261323A1 (de) | 2005-05-31 | 2010-12-15 | The Iams Company | Probiotische Katzen-Laktobazillen |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| EP2997953B1 (de) | 2006-01-18 | 2018-12-26 | Intec Pharma Ltd. | Ausgabevorrichtung zur oralen einnahme eines wirkstoffs |
| ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
| KR100714058B1 (ko) * | 2006-02-06 | 2007-05-02 | 한국유나이티드제약 주식회사 | 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법 |
| US20070202172A1 (en) * | 2006-02-24 | 2007-08-30 | Tomer Gold | Metoprolol succinate E.R. tablets and methods for their preparation |
| CA2645940A1 (en) * | 2006-03-21 | 2007-09-27 | Teva Pharmaceutical Industries Ltd. | Controlled release formulation of tolterodine |
| EP1839649A1 (de) * | 2006-03-31 | 2007-10-03 | LEK Pharmaceuticals D.D. | Beschichtete Formulierung von Tolterodine |
| JP5457830B2 (ja) * | 2006-04-03 | 2014-04-02 | オディディ，イサ | オルガノゾル被膜を含む制御放出送達デバイス |
| EP2015735A1 (de) * | 2006-04-21 | 2009-01-21 | Synthon B.V. | Tolterodin-perlen |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| WO2007131804A1 (en) | 2006-05-17 | 2007-11-22 | Synthon B.V. | Tablet composition with a prolonged release of tamsulosin |
| ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
| JP2008007458A (ja) * | 2006-06-29 | 2008-01-17 | Freunt Ind Co Ltd | レイヤリング用核粒子とその製造方法 |
| EP2591675A1 (de) | 2006-11-27 | 2013-05-15 | H. Lundbeck A/S | Heteroarylamidderivate |
| RU2436581C2 (ru) | 2007-02-01 | 2011-12-20 | Дзе Иамс Компани | Способ уменьшения воспаления и снижения стресса у млекопитающего |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| HUE073014T2 (hu) | 2007-04-25 | 2025-12-28 | Opko Renal Llc | Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén |
| KR20190028822A (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| CL2008001970A1 (es) * | 2007-07-03 | 2009-03-27 | Synthon Bv | Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva. |
| US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
| US8486452B2 (en) | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
| EP2175843B1 (de) * | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Tolterodinhaltige zusammensetzungen mit verzögerter freisetzung |
| AU2008286914B2 (en) * | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
| CA2629099A1 (en) * | 2008-04-01 | 2009-10-01 | Pharmascience Inc. | Novel oral controlled release pharmaceutical formulations |
| EP2281058B1 (de) | 2008-04-02 | 2016-06-29 | Opko Ireland Global Holdings, Ltd. | Verfahren, zusammensetzungen, verwendungen und kits mit eignung bei vitamin-d-mangel und verwandten störungen |
| WO2009140557A2 (en) * | 2008-05-14 | 2009-11-19 | Capricorn Pharma, Inc. | Modified release tolterodine formulations |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US8465770B2 (en) | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
| US9078830B2 (en) | 2009-07-31 | 2015-07-14 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| WO2011061616A2 (en) | 2009-11-23 | 2011-05-26 | Micro Labs Limited | Extended release compositions containing tolterodine and process for preparing the same |
| WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
| JO3112B1 (ar) | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| NZ706991A (en) | 2010-03-29 | 2016-08-26 | Ferring Bv | A fast dissolving pharmaceutical composition |
| WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
| WO2011137054A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120289560A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| GR1007628B (el) | 2011-07-27 | 2012-06-29 | Φαρματεν Αβεε, | Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| RU2633640C2 (ru) | 2011-09-16 | 2017-10-16 | Ферринг Б.В. | Быстрорастворимая фармацевтическая композиция |
| WO2013047795A1 (ja) * | 2011-09-30 | 2013-04-04 | アステラス製薬株式会社 | 粒子状医薬組成物 |
| CA2878784A1 (en) | 2012-07-12 | 2014-01-16 | Ferring B.V. | Diclofenac formulations |
| JP2015529255A (ja) * | 2012-09-20 | 2015-10-05 | オーエイチアール ファーマ， エルエルシーＯｈｒ Ｐｈａｒｍａ， Ｌｌｃ | 治療薬の持続放出のための多層の生体分解可能なマイクロ粒子 |
| TW201422254A (zh) | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| US20150306170A1 (en) * | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
| WO2014159051A1 (en) * | 2013-03-13 | 2014-10-02 | Advanced Bionutrition Corp. | Stable bioactive substances and methods of making |
| US20140275149A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| AU2014246617A1 (en) | 2013-12-23 | 2015-07-09 | Sun Pharmaceutical Industries Limited | Multi-layered, multiple unit pharmaceutical compositions |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| CA2936740C (en) * | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| JP6924177B2 (ja) * | 2016-02-23 | 2021-08-25 | ニプロ株式会社 | 医薬組成物粒子とそれを含む口腔内崩壊製剤 |
| JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンｄ治療法 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1144911B (it) * | 1981-03-19 | 1986-10-29 | Pharmatec Spa | Composizione farmaceutica a rilascio controllato contenente ibuprofen |
| JPH07107450A (ja) | 1993-10-08 | 1995-04-21 | Hitachi Ltd | 情報通信装置 |
| JP3453186B2 (ja) | 1994-04-14 | 2003-10-06 | 共和薬品工業株式会社 | 徐放性マイクロカプセルおよびその製造方法 |
| SE9402422D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
| US5645858A (en) * | 1994-10-06 | 1997-07-08 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| WO1998003067A1 (en) | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| US6312728B1 (en) * | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
-
1998
- 1998-11-11 SE SE9803871A patent/SE9803871D0/xx unknown
-
1999
- 1999-11-11 HK HK02102521.2A patent/HK1040917B/zh not_active IP Right Cessation
- 1999-11-11 AU AU14366/00A patent/AU762410B2/en not_active Expired
- 1999-11-11 SK SK625-2001A patent/SK284758B6/sk not_active IP Right Cessation
- 1999-11-11 UA UA2001042824A patent/UA57165C2/uk unknown
- 1999-11-11 EP EP99971702A patent/EP1128819B1/de not_active Expired - Lifetime
- 1999-11-11 GE GEAP19995939A patent/GEP20022833B/en unknown
- 1999-11-11 DE DE69910604T patent/DE69910604T2/de not_active Expired - Lifetime
- 1999-11-11 NZ NZ511430A patent/NZ511430A/en not_active IP Right Cessation
- 1999-11-11 WO PCT/SE1999/002052 patent/WO2000027364A1/en not_active Ceased
- 1999-11-11 CA CA002350061A patent/CA2350061C/en not_active Expired - Lifetime
- 1999-11-11 OA OA1200100112A patent/OA11673A/en unknown
- 1999-11-11 KR KR10-2001-7005879A patent/KR100467384B1/ko not_active Expired - Lifetime
- 1999-11-11 EA EA200100538A patent/EA005074B1/ru not_active IP Right Cessation
- 1999-11-11 HR HR20010333A patent/HRP20010333B1/xx not_active IP Right Cessation
- 1999-11-11 PT PT99971702T patent/PT1128819E/pt unknown
- 1999-11-11 SI SI9930411T patent/SI1128819T1/xx unknown
- 1999-11-11 EE EEP200100254A patent/EE05232B1/xx unknown
- 1999-11-11 PL PL99348612A patent/PL195780B1/pl unknown
- 1999-11-11 CN CNB998132160A patent/CN1169522C/zh not_active Expired - Lifetime
- 1999-11-11 US US09/763,281 patent/US6911217B1/en not_active Expired - Lifetime
- 1999-11-11 ID IDW00200101038A patent/ID30039A/id unknown
- 1999-11-11 IL IL14280999A patent/IL142809A0/xx unknown
- 1999-11-11 BR BRPI9915142A patent/BRPI9915142B8/pt not_active IP Right Cessation
- 1999-11-11 JP JP2000580595A patent/JP3616011B2/ja not_active Expired - Lifetime
- 1999-11-11 MY MYPI99004911A patent/MY122195A/en unknown
- 1999-11-11 DK DK99971702T patent/DK1128819T3/da active
- 1999-11-11 RS YUP-331/01A patent/RS49891B/sr unknown
- 1999-11-11 ES ES99971702T patent/ES2204193T3/es not_active Expired - Lifetime
- 1999-11-11 AP APAP/P/2001/002166A patent/AP1323A/en active
- 1999-11-11 HU HU0105038A patent/HU226582B1/hu unknown
- 1999-11-11 AR ARP990105734A patent/AR027815A1/es active IP Right Grant
- 1999-11-11 AT AT99971702T patent/ATE247458T1/de active
- 1999-11-11 CZ CZ20011627A patent/CZ299582B6/cs not_active IP Right Cessation
-
2000
- 2000-02-11 TW TW089102338A patent/TWI222879B/zh not_active IP Right Cessation
- 2000-02-11 TW TW089102332A patent/TWI267385B/zh not_active IP Right Cessation
-
2001
- 2001-05-03 ZA ZA200103575A patent/ZA200103575B/en unknown
- 2001-05-09 IS IS5936A patent/IS2370B/is unknown
- 2001-05-10 NO NO20012314A patent/NO331399B1/no not_active IP Right Cessation
- 2001-06-08 BG BG105582A patent/BG65149B1/bg unknown
- 2001-06-08 MA MA26228A patent/MA25325A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI222879B (en) | Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder | |
| ES2353765T3 (es) | Formulación terapeútica para administrar tolterodina con liberación controlada. | |
| EP1039882B1 (de) | Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung | |
| KR101234940B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
| KR100838930B1 (ko) | 톨테로딘을 포함하는 약학 제제 및 이의 용도 | |
| JP3580815B2 (ja) | 安定な徐放性経口投与組成物 | |
| JP5158919B2 (ja) | 延長放出経口用量組成物 | |
| JP5561885B2 (ja) | ミルタザピンの新しい配合物 | |
| US20030228359A1 (en) | Pharmaceutical formulations containing epinastine, belladonna, and pseudoephedrine | |
| US20050084527A1 (en) | Pharmaceutical formulations containing combinations of epinastine, pseudoephedrine, and methylephedrine | |
| CN101756981A (zh) | 一种布洛氯雷伪麻缓释制剂及其制备方法 | |
| JP2004035535A (ja) | 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法 | |
| JP2003523981A (ja) | モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤 | |
| WO2025054280A1 (en) | Formulations of stat3 inhibitors and methods of use thereof | |
| TW202513044A (zh) | 丙磺舒調配物 | |
| KR101199654B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
| MXPA00005215A (en) | Therapeutic formulation for administering tolterodine with controlled release | |
| HK1034664B (en) | Therapeutic formulation for administering tolterodine with controlled release |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |